MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Alkermes PLC

Fermé

SecteurSoins de santé

28.88 -0.21

Résumé

Variation du prix de l'action

24h

Actuel

Min

28.86

Max

29.08

Chiffres clés

By Trading Economics

Revenu

-124M

22M

Ventes

-123M

307M

P/E

Moyenne du Secteur

13.624

40.527

BPA

0.291

Marge bénéficiaire

7.329

Employés

1,800

EBITDA

-168M

14M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+38.65% upside

Dividendes

By Dow Jones

Prochains Résultats

23 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-1.1B

4.7B

Ouverture précédente

29.09

Clôture précédente

28.88

Sentiment de l'Actualité

By Acuity

50%

50%

115 / 375 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Alkermes PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 juil. 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 juil. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 juil. 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 juil. 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 juil. 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 juil. 2025, 15:49 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Received All Required Authorizations

4 juil. 2025, 15:48 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 juil. 2025, 15:47 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: Agreement Was Announced on Dec. 19

4 juil. 2025, 15:47 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 juil. 2025, 15:46 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 juil. 2025, 14:30 UTC

Acquisitions, Fusions, Rachats

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 juil. 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 juil. 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 juil. 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 juil. 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 juil. 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 juil. 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 juil. 2025, 12:30 UTC

Market Talk

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 juil. 2025, 12:15 UTC

Market Talk

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 juil. 2025, 12:13 UTC

Market Talk

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 juil. 2025, 12:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Comparaison

Variation de prix

Alkermes PLC prévision

Objectif de Prix

By TipRanks

38.65% hausse

Prévisions sur 12 Mois

Moyen 40 USD  38.65%

Haut 46 USD

Bas 30 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

12 ratings

8

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

27.95 / 30.91Support & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Strong Bullish Evidence

Sentiment

By Acuity

115 / 375Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.